Absci to Participate in the Stifel Healthcare Conference
November 02, 2022 16:05 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological...
Absci Welcomes Meta Senior Executive to Board of Directors
November 02, 2022 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced Meta Connectivity VP Dan Rabinovitsj as the...
Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference
October 26, 2022 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological...
Absci Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer
October 04, 2022 07:00 ET
|
Absci Corporation
- Dr. Busch transitions from Absci’s Board of Directors to Absci’s Executive Leadership team -With a proven track record advancing drugs from discovery to market, Dr. Busch brings world-class R&D...
Absci to Participate in the Morgan Stanley Global Healthcare Conference
September 01, 2022 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
Absci to Participate at the Inaugural Gilmartin Group Emerging Growth Company Showcase
August 24, 2022 07:00 ET
|
ABSCI Corporation
VANCOUVER, Wash. and NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
Absci Reports Second Quarter 2022 Financial Results and Business Update
August 11, 2022 08:00 ET
|
ABSCI Corporation
Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 ...
Absci to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
August 01, 2022 08:00 ET
|
ABSCI Corporation
VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
Absci to Participate in the SVB Securities CybeRx: Big Data, A.I. & Machine Learning in Healthcare Event
July 21, 2022 07:00 ET
|
ABSCI Corporation
VANCOUVER, Wash. and NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
Absci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires
July 14, 2022 07:05 ET
|
ABSCI Corporation
VANCOUVER, Wash. and NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...